Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Long term phase III data published in Arthritis & Rheumatology shows Lupkynis preserved kidney function up to three years in lupus nephritis patients with no new or unexpected adverse events – Aurinia Pharma

Written by | 28 Jul 2023

Aurinia Pharmaceuticals Inc. announced that full results from the Phase III, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal… read more.

Early diagnosis and monitoring of lupus nephritis — on your smartphone

Written by | 7 Feb 2023

A team of researchers at the University of Houston is reporting the success of their new method for the early diagnosis and monitoring of lupus nephritis — at… read more.

European Commission approves Benlysta for adult patients with active lupus nephritis – GSK

Written by | 13 May 2021

GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.